Eruptive epidermoid cysts resulting from treatment with imiquimod.

Abstract

BACKGROUND:

Because of its unique mechanism of action and safety profile, imiquimod, a topical immune response modifier, is used for many benign and malignant dermatologic conditions. Adverse effects are typically limited to treatment site erythema and erosion.

OBJECTIVE:

To describe a newly recognized adverse effect of imiquimod.

METHODS:

A 79-year-old woman being treated with imiquimod 5 days per week for a nodular basal cell developed a verrucous plaque over the treatment area after 7 weeks of therapy.

RESULTS:

Scouting biopsies demonstrated multiple comedones and ruptured epidermoid cysts. There was no evidence of residual basal cell carcinoma.

CONCLUSIONS:

Imiquimod is a new and novel treatment option for cutaneous malignancies. We report its successful use in the treatment of a nodular basal cell carcinoma. The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy.

• Authors: Chelsy L Marty, Henry W Randle, John S Walsh
• Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] (Dermatol Surg) Vol. 31 Issue 7 Pt 1 Pg. 780-2; discussion 782-3 (Jul 2005) ISSN: 1076-0512 [Print] United States
• PMID: 16029707 (Publication Type: Case Reports, Journal Article)

Chemical References

• Aminoquinolines
• Antineoplastic Agents
• Dermatologic Agents
• Retinoids
• Imiquimod

Topics

• Administration, Topical
• Aged
• Aminoquinolines (administration & dosage, adverse effects)
• Antineoplastic Agents (administration & dosage, adverse effects)
• Carcinoma, Basal Cell (drug therapy)
• Dermatologic Agents (administration & dosage)
• Female
• Humans
• Imiquimod
• Retinoids (administration & dosage)
• Skin Diseases (drug therapy, etiology)
• Skin Neoplasms (drug therapy)
• Treatment Outcome